Next Generation Sequencing
Support and Educational Content

Targeted sequencing for acute myeloid leukemia

xGen® Acute Myeloid Leukemia Cancer Panel v1.0

The xGen® Acute Myeloid Leukemia Cancer Panel is a target enrichment solution for next generation sequencing (NGS) composed of more than 11,500 xGen Lockdown® Probes targeting 260 genes implicated in acute myeloid leukemia (AML). This 1.2 Mb panel was developed as part of The Cancer Genome Atlas (TCGA) project collaboration [1]. The capture probes are biotin-modified oligonucleotides individually synthesized using proprietary IDT Ultramer® synthesis technology, ensuring probes of the highest quality and industry-leading yields of full-length product. The AML Cancer Panel also offers an unprecedented level of flexibility, including allowing for expansion to cover more targets, and can also be used as a supplement for exome enrichment.

The xGen AML Cancer Panel is empirically derived from 200 patient samples and achieves coverage of >99.9% of target regions with highly uniform enrichment (Figure 1). The panel is compatible with the optimized xGen 4-hour Capture Protocol, which allows sequencing to be started on the same day that target capture is performed. This stocked, functionally validated product is shipped in 1 business day after an order is received.

Figure 1. Highly uniform enrichment from xGen® AML Cancer Panel. A 4-plex target capture of human genomic DNA (Coriell) performed using the xGen AML Cancer Panel using TruSeq® LT libraries was sequenced on an Illumina MiSeq using 2 x 150 paired-end reads. A cumulative 31.8M reads were generated for all 4 samples. Greater than 98% of targets are covered at >0.2 of the mean coverage. Mean coverage depth ranged from 218X to 510X as a result of expected sample-to-sample variability.

To order the xGen AML Cancer Panel, or for more information about this and other NGS products from IDT, go to xGen Lockdown Panels.

References

  1. Cancer Genome Atlas Research Network (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med, 368(22):2059–2074.

Product focus: Target capture reagents from IDT


xGen® Lockdown® Probes

xGen Lockdown Probes are individually synthesized, quality controlled, and normalized hybridization probes that offer:

  • Sensitive detection of SNPs, indels, CNV, LOH, and translocations
  • GMP compliance for clinical and diagnostics research
  • Flexibility to augment existing panels or create completely custom panels
  • Quick delivery

Discover more about xGen Lockdown Probes.


xGen Lockdown Panels

xGen Lockdown Panels are preconfigured, validated, and stocked pools of xGen Lockdown Probes for targeted next generation sequencing of defined gene families:

  • xGen Exome Research Panel
  • xGen Acute Myeloid Leukemia Cancer Panel
  • xGen Pan-Cancer Panel
  • xGen Inherited Diseases Panel
  • xGen Human ID Research Panel
  • xGen Human mtDNA Research Panel

Discover more about xGen Lockdown Panels.


xGen Lockdown Reagents Hybridization and Wash Kit

Achieve uniform coverage with hybridization and wash buffers that are optimized for target enrichment using xGen Lockdown Probes and Panels. A short, 4-hour hybridization protocol generates results quickly.

Discover more about xGen Lockdown Reagents.


xGen Blocking Oligos

xGen Universal Blocking Oligos for single- or dual-index adapters used with common sequencing platforms improve on-target performance for multiplexed samples by reducing adapter participation in hybridization enrichment. Custom adapters can be manufactured for other barcodes or to meet the needs of customers who require specific modifications or services to improve performance in unique applications.

Discover more about xGen Blocking Oligos.

Related reading

Next generation sequencing for risk assessment in acute myeloid leukemia—Citation summary: Read how these researchers use next generation sequencing (NGS) techniques with patients diagnosed with AML to identify associations between specific mutations and disease outcome. These techniques were also used to track the elimination of leukemia-specific mutations in AML patients following chemotherapy. The IDT xGen® AML Cancer Panel v1.0 was used to target and capture 264 commonly mutated genes in AML.T

Gene panels vs. gene-by-gene analysis for assessing disease risk—Citation summary: These authors compared an NGS-based gene panel and traditional testing data for diagnostic use and disease risk assessment in hereditary breast and ovarian cancer. Read how xGen Lockdown Probes (IDT) were able to rescue drop-out regions of SureSelect (Agilent) probe panels.

Targeting cancer pathways: Sensitive, comprehensive detection of genomic alterations using a custom NGS panel—Citation summary: Learn how researchers use xGen Lockdown Probes to screen cancer samples for key genes related to targeted cancer therapies.


Review other DECODED Online newsletter articles on NGS applications.

You can also browse our DECODED Online newsletter for additional application reviews, lab tips, and citation summaries to facilitate your research.

Author: Nicola Brookman-Amissah, PhD, is a senior scientific writer at IDT.

© 2014, 2017 Integrated DNA Technologies. All rights reserved. Trademarks contained herein are the property of Integrated DNA Technologies, Inc. or their respective owners. For specific trademark and licensing information, see www.idtdna.com/trademarks.


xGen® Blocking Oligos

Adapter blocking oligos increase the number of on-target reads by preventing non-specific binding during hybridization.

Find blockers for your platform ≫


Related Articles

Target Enrichment Facilitates Focused Next Generation Sequencing

The rationale and benefits of enriching subsets of the genome (target enrichment by hybrid capture) prior to sequencing.

Read more ≫

Improving Uniform Coverage of Targeted Sequences for NGS

The challenges faced in obtaining uniform coverage of NGS data and how IDT xGen® Lockdown® Probes are uniquely positioned to facilitate uniform sequence coverage.

Read more ≫

Towards Providing Personalized Medicine—Considerations for Reliable NGS Data

Geneseeq Technology, Inc. demonstrates how they improved their target capture methods to increase accuracy in clinical diagnostics by using optimized blocking oligos and stringent hybridization conditions.

Read more ≫

Delivering Comprehensive Genomic Profiling for Clinical Cancer Care Using Targeted Sequencing

Read how scientists at Foundation Medicine, Inc use hybrid selection in their FoundationOne® Test to help clinicians select patient specific treatment options.

Read more ≫

Insertion Site Detection and Targeted RNA Capture Using Next Generation Sequencing

Scientists at Cofactor Genomics use in-solution hybridization to focus on regions of interest for next generation sequencing.

Read more ≫